Europe Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

The Europe infectious disease diagnostics market was valued at US$12.26 billion in 2022 and is expected to reach US$19.02 billion by 2030; it is estimated to grow at a CAGR of 5.6% from 2022 to 2030.

Rising Application of Diagnostics in Veterinary Infectious Disease Drives Europe Infectious Disease Diagnostics Market

Veterinary infectious diseases negatively impact the health of domestic animals, livestock, and wildlife. As a result of intensive animal farming, there are conditions for the emergence and amplification of disease epidemics due to the genetic and physical proximity of the billions of animals, often in frail health, that are raised indoors every year. Moreover, animal farming contributes to the spread of infections from wild animals due to deforestation caused by the expansion of agricultural land use.

Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential to reduce economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally to detect animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, susceptible, and specific, with the ability to detect at a high volume.

Even though conventional virological methods are incredibly reliable, they are time-consuming and labor-intensive procedures. Lateral flow and enzyme-linked immunosorbent assay can be used for rapid detection. Multiplex bead immuno or Luminex assay is a fluorescent beads-based high-throughput quantitative technique used for the detection of multiple antibodies specific for different infectious diseases at the same time in a single reaction, leading to more rapid, economical, and accurate results compared with conventional ELISA. In addition, the protein chip based on surface plasmon resonance (SPR) appears to be a rapid valuable tool in the sero-diagnosis of infection or antibody titration. Recombinant antibodies can also be produced in heterologous systems by using rDNA technology and used for developing diagnostic tests.

Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating African swine fever virus, classical swine fever virus, avian influenza virus, and foot-and-mouth disease virus for research purposes. The genesig detection kits of Primerdesign Ltd, UK supply lyophilized qPCR assay kits for the diagnosis of 62 bovine, 42 equine, 47 porcine, 60 avian, 40 canine, and 26 feline pathogens for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR. Thus, diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals is fueling the diagnostics in veterinary diagnosis.

Europe Infectious Disease Diagnostics Market Overview

According to the data published in an article by the Robert Koch Institute, ~3,900 tuberculosis cases were registered in Germany in 2021. Furthermore, ~5% of the test-site visitors in Germany had STD. Also, the number of annual visitors for chlamydia and gonorrhea tests had increased from 17% (2017) to 42% (2020). According to The Robert Koch Institute, in Germany, approximately 400,000-600,000 patients suffer from HAIs each year; and about 10,000-15,000 of them die due to the infection. Healthcare providers also suffer from various other medical conditions, including surgical site infections, urinary tract infections, and pneumonia.

According to HPV ICO/IARC Information Centre on HPV and Cancer, Fact Sheet 2021, in Germany, ~36.7 million women aged above 15 years are at risk of developing cervical cancer. According to the current estimates, every year, about 4,700 women are diagnosed with cervical cancer, and ~2,100 die from the disease. Cervical cancer is recorded to be the 14th most common type of cancer among women in Germany and the third-most common type of cancer among women between 15 and 44 years of age. About 3.2% of women in the general population are suffering from cervical HPV-16/18 infection at a given time in their lifetime, and ~76.5% of invasive cervical cancers are due to HPVs 16 or 18. The prevalence of various infectious diseases in Germany is fueling the growth of the market in the country.

In March 2022, SCIENION completed PoC-BoSens, the diagnostic research project led by the Fraunhofer Institute for Reliability and Microintegration (IZM). The PoC-BoSens is an innovative label-free Point-of-Care device based on 3-D photonic bottle resonators (3D-BMRs) for accurate measurement of disease-relevant biomolecules. Thus, owing to the above-mentioned factors, the market for infectious disease diagnostics is likely to grow during the forecast period.

Europe Infectious Disease Diagnostics Market Segmentation

The Europe infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.

Based on product, the Europe infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.

By technology, the Europe infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the Europe infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.

By testing type, the Europe infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the Europe infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.

Based on country, the Europe infectious disease diagnostics market is segmented into Germany, the UK, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe infectious disease diagnostics market in 2022.

Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the Europe infectious disease diagnostics market.